Symbiotix Biotherapies is developing a novel class of molecular therapeutics derived from the human microbiome that modulate regulatory T cell (TREG) activity. Its programs center on ReglemersTM, first-in-class molecules, and the company’s lead clinical candidate SYMB-104. SYMB-104 is covered by a composition-of-matter patent (U.S. 9,539,281) and the company’s intellectual property portfolio includes 22 issued patents with multiple pending cases licensed from Caltech, Brigham and Women’s Hospital, and Dartmouth College. The company’s scientific co‑founders include Dennis Kasper, Sarkis Mazmanian, and Lloyd Kasper, and its work is built on over two decades of research at those institutions. Symbiotix is positioning to commence human clinical trials and is focused on delivering oral agents for inflammatory bowel disease, multiple sclerosis and other immune-mediated diseases. Financially, the company has attracted significant non-dilutive capital historically and recently completed an institutional equity financing to advance clinical readiness. Symbiotix Biotherapies is a Boston-based company developing a novel class of molecular therapeutics derived from the human microbiome. Its lead clinical candidate, Polysaccharide A (PSA), is described as the first potentially therapeutic molecule to emerge from the microbiome and a first-in-class oral therapy for immune-mediated diseases. PSA is reported to act by activating regulatory T cells, producing potent anti-inflammatory effects, and is being developed for inflammatory bowel disease (IBD) and other disorders including multiple sclerosis. The $2.0 million Phase II STTR award from the NIDDK will fund completion of key translational studies and process development/manufacturing needed to move PSA into human clinical trials. This award is Symbiotix’s fourth NIH award, bringing NIH funding to over $5.0 million to date. The company was founded on research at Brigham & Women’s Hospital/Harvard Medical School, California Institute of Technology, and Dartmouth College, and cites over two decades of scientific research and robust intellectual property supporting its programs. Leadership noted in the articles includes co-founder Prof. Sarkis Mazmanian and President & CEO Nader Yaghoubi.

Total raised

$7M

Funding rounds

2

Latest round

Equity

Latest activity

Nov 2017